Spotlight Innovation has obtained an exclusive, worldwide license to STL-182, a novel compound invented by Drs. Elliot Androphy at Indiana University and Kevin Hodgetts, director of the Laboratory for Drug Discovery in Neurodegeneration at Brigham and Women's Hospital. The investigators' successful research collaboration was supported in part by a series of grants from the National Institutes of Health.

Spotlight Innovation plans to develop and commercialize STL-182 for treatment of patients with spinal muscular atrophy (SMA). STL-182 is an orally-available small molecule that stabilizes SMN protein, causing it to last longer.

Dr. Androphy is a member of the Cure SMA Scientific Advisory Board and, together with Dr. Hodgetts, recently received a grant from Cure SMA for development of another novel series of compounds. These compounds target SMN2, the SMA “backup gene,” in an effort to prompt SMN2 to produce more SMN protein. “I truly appreciate all the support of Cure SMA has provided over the years and am hopeful that this work will come to fruition for those affected by SMA,” said Dr. Androphy.

2016 Heighlights

2015 Heighlights